圣诺生物：预计前三季度净利润同比增长100.53%-145.10%

Core Viewpoint - The company expects a net profit of 114 million to 140 million yuan for the first three quarters of 2025, representing a year-on-year growth of 100.53% to 145.10% [1] Group 1: Financial Performance - The company's main business is experiencing stable development, contributing to significant growth in overall performance [1] - The demand for orders in the peptide raw material business continues to grow, driven by the ongoing capacity expansion [1] Group 2: Market Position - The company maintains strong market competitiveness and sustainable profitability due to substantial performance growth compared to the same period last year [1]